ALZA

Sep 25, 03
12:12 ET	New Drug Application Submitted for Needle-Free E-TRANS(R) Fentanyl HCl
Jun 05, 02
08:02 ET	ALZA Corporation and TransForm Pharmaceuticals to Collaborate on Drug Optimization
Jul 03, 01
15:49 ET	Study Compares Extended-Release Function of Leading Overactive Bladder Medications
Jun 21, 01
13:04 ET	ALZA Stockholders Approve Merger Agreement With Johnson & Johnson
Apr 26, 01
16:02 ET	ALZA Reports Financial Results for First Quarter 2001
Apr 13, 01
17:00 ET	ALZA Corporation Conference Call
Apr 10, 01
07:30 ET	ALZA Corporation Announces Positive Results of O.B.J.E.C.T. Study, Comparing Leading Therapies for Overactive Bladder Symptoms
Apr 06, 01
18:41 ET	ALZA Corporation to Report Results of O.B.J.E.C.T. Study on April 10, 2001
Feb 27, 01
13:25 ET	ALZA Corporation Outlines Strategy for Growth in 2001
Feb 21, 01
18:14 ET	ALZA Corporation to Host Analyst Meeting and Provide Web Cast On February 27, 2001
Feb 15, 01
14:00 ET	ALZA and Northbay Healthcare Foundation Announce Plans for New Emergency Facilities
Feb 05, 01
07:01 ET	ALZA Acquires Flexeril(R) Product and Trademark in United States and Canada
Feb 01, 01
06:00 ET	Alza Corporation Announces Plans to Establish Manufacturing Facility In Cashel, Ireland
Jan 30, 01
08:04 ET	ALZA'S CAELYX(R) Approved in Canada for Treatment of Advanced Ovarian Cancer
Jan 25, 01
16:02 ET	ALZA Reports 2000 Financial Results
Jan 23, 01
17:39 ET	ALZA Corporation to Announce Fourth Quarter and 2000 Earnings On Thursday, January 25
Jan 09, 01
17:30 ET	ALZA Announces Expansion of Ditropan XL(R) Promotion to Primary Care Audience At JP Morgan H&Q Healthcare Conference
17:30 ET	ALZA and UCB Pharma Extend Ditropan XL(R) Co-Promotion Agreement
Jan 08, 01
12:41 ET	Jerry T. Jackson Joins ALZA Corporation's Board of Directors
Dec 12, 00
09:01 ET	Concerta(TM) Now to Be Available in Three Doses
Oct 31, 00
15:30 ET	ALZA Stockholders Approve 2-for-1 Stock Split and Increase in Authorized Shares
Oct 26, 00
08:02 ET	ALZA Corporation Unblinds O.B.J.E.C.T. Study Comparing Leading Therapies For Overactive Bladder Symptoms
Oct 19, 00
16:00 ET	ALZA Reports Financial Results for Third Quarter 2000
Oct 04, 00
18:36 ET	ALZA Corporation and MedImmune Announce Publication of Pivotal Ethyol(R) Data In Journal of Clinical Oncology
Oct 02, 00
09:01 ET	ALZA Exercises Option to Acquire Crescendo Pharmaceuticals Corporation
Sep 12, 00
09:01 ET	ALZA Announces 2-for-1 Stock Split
Aug 31, 00
09:02 ET	Long Term Study Shows Once-a-Day Oxybutynin Improves Quality of Life For Patients With Overactive Bladder With Fewer Discontinuations Than Conventional Oxybutynin
Aug 30, 00
09:01 ET	University of Pittsburgh Researchers Conduct First Head-to-Head Study Of Ditropan XL and Detrol for Treatment of Overactive Bladder
Aug 23, 00
21:00 ET	Crescendo Board of Directors Declares Special Cash Dividend
Aug 21, 00
20:34 ET	Conversion of ALZA'S 5% Convertible Debentures Completed
Aug 01, 00
20:05 ET	ALZA CORPORATION CONFERENCE CALL
Jul 28, 00
12:30 ET	ALZA Announces Closing of Zero Coupon Convertible Subordinated Debentures
Jul 25, 00
09:09 ET	ALZA Announces Pricing of Zero Coupon Convertible Subordinated Debentures in Private Offering
Jul 24, 00
12:39 ET	ALZA to Offer Zero Coupon Convertible Subordinated Debentures
May 18, 00
13:27 ET	ALZA and Crescendo Announce Receipt of FDA Approvable Letter for Concerta(TM)
May 17, 00
12:00 ET	ALZA Announces Results of Follow-Up Study Evaluating the Efficacy and Safety Of Once-Daily Concerta(TM) Methylphenidate HCl Extended-Release Tablets (CII) For Treatment of ADD/ADHD
May 10, 00
07:30 ET	ALZA and Bayer Announce Two U.S. Co-Promotion Agreements
May 04, 00
18:02 ET	ALZA Announces Results of Study Evaluating the Efficacy and Safety Of Concerta(TM) (methylphenidate HCL) Extended-Release Tablets for Treatment Of ADD/ADHD
Apr 18, 00
16:06 ET	ALZA Announces 2000 First Quarter Financial Results
08:03 ET	ALZA and McNeil Announce U.S. Co-Promotion Agreement for Concerta(TM)
Mar 06, 00
09:47 ET	ALZA Announces Approval of Viadur(TM) for Once-Yearly Palliative Treatment of Advanced Prostate Cancer
Jan 27, 00
16:01 ET	ALZA Reports 1999 Financial Results
16:01 ET	American Power Conversion Announces Record Fourth Quarter Results Highlighted by Net Income Growth of 40 percent
Jan 26, 00
12:14 ET	ALZA Corporation Announces Vice President Promotions
Jan 20, 00
21:32 ET	ALZA and Abbott Complete Merger Termination
Jan 10, 00
10:30 ET	ALZA Corporation Announces Senior Management Promotions
Dec 20, 99
09:01 ET	ALZA Corporation Adopts Stockholder Rights Plan
Dec 16, 99
16:16 ET	ALZA and Abbott Announce Proposed Merger Will Not Be Completed
Oct 25, 99
09:01 ET	Clinical Results of Once-Daily Treatment for ADD/ADHD Announced by ALZA And Crescendo Pharmaceuticals
Oct 20, 99
16:06 ET	ALZA Reports Record Financial Results for Third Quarter 1999
Sep 21, 99
12:55 ET	ALZA Corporation Stockholders Approve Merger Agreement With Abbott Laboratories
Sep 20, 99
12:00 ET	ALZA Corporation Press Release
Aug 25, 99
09:00 ET	Study Evaluates Long-Term Continuation Rate With ALZA's Ditropan(R) XL As Once-A-Day Treatment for Overactive Bladder
Aug 16, 99
18:17 ET	ALZA Sets Special Stockholders Meeting Date to Approve Proposed Merger With Abbott for September 21, 1999
Aug 12, 99
09:00 ET	ALZA Announces European Submission for Ditropan(R) XL
Jul 22, 99
16:02 ET	ALZA Announces 1999 Second Quarter Financial Results
09:01 ET	ALZA Expands Sales Effort for Ditropan(R) XL
Jul 21, 99
09:01 ET	NDA Submission for OROS(R) Methylphenidate Announced by ALZA and Crescendo Pharmaceuticals
Jun 29, 99
09:00 ET	ALZA's Doxil(R) Approved for the Treatment of Refractory Ovarian Cancer
Jun 24, 99
16:26 ET	U.S. Bioscience and ALZA Corporation Announce FDA Approval of Ethyol(R) To Reduce Radiation-Induced Xerostomia (Dry Mouth)
09:00 ET	ALZA Corporation Announces Approval of Ditropan(R) XL 15 mg Tablets
Jun 10, 99
09:00 ET	ALZA Corporation Launches Direct-to-Consumer Campaign on Overactive Bladder And Treatment
Jun 08, 99
19:02 ET	U.S. Bioscience and ALZA Corporation Announce Positive FDA Panel Recommendation for Ethyol(R)
13:52 ET	FDA Advisory Committee Recommends ALZA's Doxil(R) for Approval in Treatment Of Refractory Ovarian Cancer
May 26, 99
10:00 ET	ALZA Submits New Drug Application for Viadur(TM)
10:00 ET	Crescendo Announces Submission of New Drug Application for DUROS(R) Leuprolide
May 19, 99
10:00 ET	Pivotal Phase III Clinical Study Results of ALZA's Ditropan(R) XL Presented For First Time at ACOG Meeting
Apr 21, 99
16:30 ET	ALZA Announces 1999 First Quarter Financial Results
Apr 15, 99
11:06 ET	Supplemental NDA for ALZA's Doxil(R) in Refractory Ovarian Cancer Granted Priority Review
Mar 16, 99
13:35 ET	ALZA Acquisition of SEQUUS Approved
Mar 08, 99
11:00 ET	Alza's Ditropan(R) XL New Drug Submission Accepted for Review in Canada
Feb 11, 99
16:01 ET	ALZA & SEQUUS Announce Effectiveness of Registration Statement
16:01 ET	ALZA Reports on 1998 Milestones and Outlines Priorities for 1999
Feb 01, 99
08:02 ET	Ditropan(R) XL Now Available in Pharmacies to Millions of Americans With Overactive Bladder
03:30 ET	Ditropan(R) XL Now Available in Pharmacies to Millions of Americans With Overactive Bladder
Jan 28, 99
16:01 ET	ALZA Announces 1998 Financial Results
Dec 17, 98
08:58 ET	ALZA Announces European Marketing Agreement with Synthelabo for OROS Oxybutynin
08:55 ET	ALZA's Ditropan XL Approved for Treatment of Overactive Bladder
Nov 17, 98
14:28 ET	ALZA Corporation and SEQUUS Pharmaceuticals, Inc. Announce Expiration Of Hart-Scott-Rodino Waiting Period
Nov 03, 98
16:05 ET	ALZA Acquires Urispas(R) in the U.S. From Smithkline Beecham
Oct 20, 98
12:02 ET	ALZA Appoints Vice Presidents in R&D
Oct 15, 98
16:07 ET	ALZA Announces Third Quarter Financial Results
Oct 12, 98
11:00 ET	ALZA Announces Launch of Testoderm with Adhesive In The People's Republic of China
Oct 05, 98
09:03 ET	ALZA To Acquire SEQUUS
Sep 29, 98
11:00 ET	ALZA Acquires Rights to MacroBID(R) and Macrodantin(R) Products in Canada
Aug 13, 98
14:53 ET	ALZA Doubles Sales Effort for Ditropan(R) XL
13:00 ET	ALZA Announces Senior Level Promotions in Human Resources and Finance
Jul 28, 98
12:36 ET	Mary Bordeaux Joins ALZA as Vice President of Health Systems
Jul 15, 98
16:15 ET	ALZA Announces Second Quarter Financial Results
Jul 08, 98
16:36 ET	ALZA Expands Sales Organization to Address Growing Portfolio of Urology And Oncology Products
Jun 29, 98
10:00 ET	ALZA Exercises Option to Acquire ALZA TTS Research Partners, Ltd.
09:01 ET	Randomized Clinical Study Results of Ditropan(R) XL Reported at Major International Meeting on Incontinence
Jun 04, 98
09:00 ET	Phase I/II Clinical Study Results of DUROS(TM) Leuprolide Implant for Prostate Cancer Treatment Announced at AUA Meeting
Jun 01, 98
09:00 ET	Phase III Clinical Study Results of Ditropan(R) XL for Once-Daily Treatment Of Urge Urinary Incontinence Presented at AUA
May 28, 98
14:16 ET	ALZA Promotes Susan Rinne to Vice President, Regulatory Affairs
May 18, 98
12:45 ET	New Ethyol(R) Data Presented by U.S. Bioscience at ASCO Demonstrates Reduction Of Radiation Therapy Toxicities in Head and Neck Cancer
Apr 16, 98
09:00 ET	ALZA Announces First Quarter Financial Results
Mar 11, 98
09:00 ET	ALZA Introduces Testoderm(R) TTS for Testosterone Deficiency
09:00 ET	National Survey Finds Testosterone, the Essential Male Hormone, is a Mystery To Most Men
Feb 25, 98
15:30 ET	ALZA Promotes Jay Shepard to Vice President, Sales
Jan 22, 98
12:50 ET	ALZA Announces 1997 Financial Results
Jan 19, 98
08:02 ET	Franco Di Muzio Appointed to Head ALZA's International Operations
Jan 15, 98
15:27 ET	ALZA Promotes Janne Wissel to Sr. Vice President, Operations
Jan 12, 98
11:43 ET	ALZA and Janssen to Collaborate on E-TRANS(TM) Pain Products
Dec 22, 97
10:05 ET	ALZA Submits New Drug Application For Ditropan(R) XL
Dec 19, 97
09:00 ET	ALZA Receives FDA Clearance to Market Testoderm(R) TTS; New Patch Provides Both Convenience and Comfort
Dec 01, 97
13:03 ET	ALZA Enters U.S. Distribution Agreement with Warner-Lambert for OROS Pseudoephedrine; Product to Be Launched Under Sudafed(R) 24-Hour Brand Name
Nov 20, 97
16:45 ET	ALZA Corporation Trims Approximately 90 Positions From Workforce
Nov 17, 97
11:26 ET	ALZA and SmithKline Beecham Sign International Commercialization Agreement For Nicoderm
Nov 14, 97
08:02 ET	Dr. Alejandro Zaffaroni to Retire From ALZA and Affymetrix Boards
Nov 06, 97
15:40 ET	Crescendo Pharmaceuticals Corporation Announces Appointment to Board of Directors
Oct 27, 97
17:50 ET	Crescendo Pharmaceuticals Corporation Announces Appointments to Board of Directors
15:25 ET	Karen Bergman Joins ALZA as Vice President, Corporate and Investor Relations
Oct 20, 97
15:11 ET	ALZA Completes Acquisition of Ditropan(R) Product and Trademark in the United States
Oct 15, 97
08:11 ET	ALZA Announces Third Quarter Financial Results
Oct 09, 97
09:15 ET	ALZA Initiates Phase III Prostate Cancer Studies for First Product Incorporating DUROS(TM) Implant Technology
Sep 30, 97
10:00 ET	Alza Acquires Ditropan(R) Product and Trademark in the United States
09:01 ET	ALZA Distributes Shares of Crescendo Pharmaceuticals Corporation
Sep 18, 97
08:00 ET	ALZA to Acquire IVAX'S Elmiron(R) and Other Urology Products In the U.S. and Canada
Sep 08, 97
11:31 ET	ALZA Announces Special Distribution of Shares of Crescendo Pharmaceuticals Corporation
Aug 26, 97
09:02 ET	ALZA Exercises Option to Acquire Therapeutic Discovery Corporation
Aug 21, 97
14:56 ET	ALZA Announces New Vice President Promotions
Aug 01, 97
13:15 ET	ALZA Announces Organizational Changes in R&D
Jul 15, 97
11:30 ET	ALZA Files Registration Statement for Crescendo Pharmaceuticals Corporation
10:04 ET	Therapeutic Discovery Corporation Announces Second Quarter Financial Results
10:03 ET	ALZA Announces Second Quarter Financial Results
Jul 09, 97
15:23 ET	ALZA Enters International Commercialization Agreement with Pfizer for OROS(R) Pseudoephedrine
Jul 01, 97
16:26 ET	ALZA Appoints Vice Presidents of Clinical Research, Marketing
12:16 ET	ALZA Acquires Mycelex(R) Troche in the U.S. From Bayer
Apr 30, 97
12:08 ET	Phase I/II Prostate Cancer Studies Underway for First Product Incorporating ALZA's DUROS(TM) Implant Technology
Apr 17, 97
13:20 ET	ALZA Corporation Promotes Dr. James Brown to Vice President, DUROS(TM) Technologies
Apr 15, 97
12:23 ET	ALZA Announces First Quarter Financial Results
Apr 14, 97
11:54 ET	ALZA and SmithKline Beecham Sign Commercialization Agreement for Nicoderm(R) in China and Japan
Feb 13, 97
16:13 ET	ALZA and Alkermes Announce $50 Million Stock Purchase Agreement and Product Development Collaboration
15:00 ET	ALZA Updates Status of Products Under Development with TDC and Discloses New Technologies at Annual Analyst Meeting
Feb 11, 97
11:03 ET	ALZA Signs Agreement With Knoll to Develop and Commercialize OROS(R) Hydromorphone Product
Jan 27, 97
13:03 ET	International Commercialization Agreements Signed for ALZA's Transdermal Testosterone Products
Jan 22, 97
12:50 ET	ALZA Announces 1996 Financial Results
Nov 25, 96
17:12 ET	ALZA Corporation Promotes Peter Staple and Bruce Cozadd to Senior Vice President
Oct 15, 96
14:00 ET	ALZA Announces Third Quarter Financial Results
Oct 07, 96
13:30 ET	New Formulation of Testoderm(R) (testosterone transdermal system) CIII Now Available in the U.S.
Aug 20, 96
12:23 ET	SmithKline Beecham's NicoDerm CQ Now Available in Stores: Number One Prescription Nicotine Patch Available Over-the-Counter
Aug 14, 96
14:35 ET	ALZA Appoints Two New Members to Board of Directors
Aug 12, 96
14:53 ET	Court Upholds Dismissal of Cygnus Lawsuit Against ALZA
Jul 17, 96
12:18 ET	ALZA ANNOUNCES SECOND QUARTER FINANCIAL RESULTS
Mar 30, 96
11:00 ET	ALZA Announces Senior Management Promotions